Treatment patterns among moderate-to-severe ulcerative colitis patients in TARGET-IBD

The treatment paradigm for moderate-to-severe UC was expanding rapidly with new biologics and JAK inhibitors, but real-world data characterizing treatment modification patterns—switching, dose escalation, augmentation—across advanced and conventional therapies had not been quantified in a large prospective US cohort.

The TARGET-IBD registry was used to estimate the risk of treatment modification among moderate-to-severe UC patients initiating advanced or conventional therapies, using Fine-Gray sub-distribution hazard regression with funding from Bristol Myers Squibb.

Demonstrating that patients initiating advanced therapies are less likely to require treatment modification than those on conventional therapies provides real-world comparative effectiveness evidence for the durability of biologics and JAK inhibitors in UC, supporting BMS's commercial and prescriber education strategy.

Real-world treatment modification rate benchmarking for UC advanced therapy durability evidence, Comparative effectiveness of advanced vs. conventional therapy in moderate-to-severe UC for prescriber education, BMS-funded UC treatment pattern evidence supporting label and payer strategy for advanced therapies